Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a liquid biopsy for infectious diseases. The Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 7, 2022 | Series B | — | 2 | — | — | Detail |
| Jan 20, 2021 | Series B | — | 1 | — | — | Detail |
| Feb 24, 2020 | Series B | $165M | 5 |
SoftBank Vision Fund
|
— | Detail |
| Nov 30, 2018 | Debt Financing | $25M | 1 |
|
— | Detail |
| Aug 5, 2017 | Series A | $59M | 8 |
DCVC
Lightspeed Venture Partners
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
SoftBank Vision Fund
|
Yes | Series B |
|
|
Yes | Debt Financing |
DCVC
|
Yes | Series A |
HBM Healthcare Investments AG
|
— | Series B |
HBM Partners
|
— | Series B |
General Catalyst
|
— | Series B |
Khosla Ventures
|
— | Series B |
Lightspeed Venture Partners
|
— | Series B |
aMoon Fund
|
— | Series A |
Innovation Endeavors
|
— | Series A |